[{"orgOrder":0,"company":"University of Washington","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Iodixanol","moa":"iodine-containing contrast media","graph1":"Oncology","graph2":"Phase I","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Washington \/ GUERBET","highestDevelopmentStatusID":"6","companyTruncated":"University of Washington \/ GUERBET"}]
Find Clinical Drug Pipeline Developments & Deals for Iodixanol
Details :
Iodixanol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Head and Neck Neoplasms.
Reset All
